Navigation Links
Cannabis Science (CBIS) Moves Forward with Critical Support of Landmark Federal Cannabis Legislative Initiative
Date:12/2/2013

COLORADO SPRINGS, Colo., Dec. 2, 2013 /PRNewswire/ -- (NASDAQ OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development, is a key leader in the private sector challenge to end the restrictions on cannabis drug development and research in the U.S.  "The Cannabinoid Scientific Research and Development Act," which will be submitted for congressional review in the U.S. Senate and House of Representatives by the end of January 2014, is landmark legislation seeking equal treatment for cannabinoid scientific research.  In addition, the legislation aims to provide the framework for the clinical investigation of the hundreds of strains of cannabis and their constituent cannabinoids regarding their medical efficacy on a wide range of life-threatening, chronic, and infectious diseases. 

The legislation also seeks to provide "an informed clinical environment for physicians, researchers and consumers to make effective clinical choices regarding their therapeutic treatments for a variety of diseases," said Dr. Robert Melamede, President, Cannabis Science.  "We need rational federal standards based upon science to replace inadequate public policies rooted in the misperceptions of the past," Dr. Melamede added.

The legislation directs the U.S. Secretary of Health and Human Services to develop guidelines, standards, and regulations that provide the framework for development of cannabis research.  It also asks that this new regulatory framework begin rapidly after the removal of legal and regulatory obstacles for that research and that these guidelines follow a milestone 2007 Drug Enforcement Administrative Law ruling overturning the prejudicial procedures that effectively disallow domestic cannabis research and drug development.

Cannabis Science views these federal legislative developments as a critical part of the growth and development of its domestic biotechnology business.  "We need the same consideration in terms of the ability to conduct clinical trials and to develop therapies as other firms in the biotechnology sector," said Dr. Dorothy Bray, CEO of Cannabis Science.  Dr. Bray continued, "We also need to level the playing field to match rapidly changing regulatory environment in other countries that either have or are accommodating cannabis research."

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and HIV related cancers such as Kaposi's sarcoma.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
www.cannabisscience.com

Investment Inquiries
Robert Kane, CFO & Director
rkane@cannabisscience.com
561.420.4824


'/>"/>
SOURCE Cannabis Science, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GrowLife Debuts First Kiosk-Based Payment, Cash Management, and Regulatory Compliance Technology for Legal Cannabis Dispensaries
2. Cannabis Science Announces The Depository Trust Company (DTC) Lifts Share Trading "Chill" Effective Immediately
3. X-Change Corp. Delighted with DOJs Historic Shift Toward Non-Interference Within State Cannabis Regulatory Environments; Sees Green Light for Companys Patient-Driven Medical Cannabis Operations Under State Laws
4. X-Change Corporation Signs Multi-Million Dollar Agreement for Multi-State Product Release Licensing, Medical Cannabis Dispensary Management, and Cultivation Consulting
5. American Drug War II: Cannabis Destiny is IMDBs Highest Rated 2013 Documentary
6. Cannabis Science Appoints Clinical Development Expert, Dr. Dorothy Bray, as Chief Executive Officer (CEO) and Director, Focusing on CS-TATI-1 and Building Companys Drug Development Pipeline
7. Virogens New Business Unit, "The Cannabis Connection," to Focus on High-End Medicinal Marijuana Dispensary Niche within $15-20 Billion Legal Marijuana Market
8. Virogen Announces Launch of New Business Unit, "The Cannabis Connection", and Sets Sights on $15-20 Billion Legal Marijuana Market
9. Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
10. Abattis Provides $10,000 Sponsorship to the American Herbal Pharmacopoeia for Cannabis Monograph Project
11. Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)...  Community pharmacists can help improve medication adherence and ... a custom-built medication synchronization program, Cardinal Health MedSync Advantage™. ... Schieber Family Pharmacy in Circleville, ... patients enrolled in this medication synchronization program, which is ... the patient, and it,s a win for us because ...
(Date:2/11/2016)... , Feb. 11, 2016  Delcath Systems, Inc. ... medical device company focused on oncology with an ... liver cancers, announces the engagement of Lars ... Global Medical Consultant. Dr. Birgerson will provide strategic ... clinical operations team to help ensure timely facilitation ...
(Date:2/11/2016)... Scientists from Silicon Biosystems Menarini today ... door to genetic analysis of previously preserved tumor ... isolate with 100 percent purity. Utilizing the com­pany,s ... various stages of development, the researchers were able ... are clinically relevant, and may change the way ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... Student-doctors from Western University of ... Program Tuesday, February 9, taking one of the final steps in their medical ... positions across the country. Of the 103 student-doctors who comprise the College of ...
(Date:2/11/2016)... , ... February 11, 2016 , ... Florida Hospital presents ... take on the St. Louis Blues at the Amalie Arena. The puck drops at ... walk-through heart exhibit, the MEGA Heart, prior to the game. The MEGA Heart will ...
(Date:2/11/2016)... ... February 11, 2016 , ... The president released a ... Health System but would shift more of the cost burden to military beneficiaries. ... laid out in the defense budget as including limited quantifiable benefit fixes mixed with ...
(Date:2/11/2016)... Petersburg, FL (PRWEB) , ... February 11, 2016 ... ... providers and advocates will discuss how to improve care by making data on ... pediatric heart disease. The Summit on Transparency and Public Reporting of Pediatric and ...
(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, ... Benefit Model: A Case Study for Plans and Purchasers.” Executives from Intel Corp. ... with Intel on value-based health benefits program Connected Care, will discuss the challenges ...
Breaking Medicine News(10 mins):